Vidac Pharma Holding plc reports preclinical proof of principle
Vidac Pharma Holdings plc will report promising results for its cancer drug candidate VDA-1275 in multiple mouse cancer and human cellular...
Scientists create non-digestible aptamer
The synthetic TNA nucleic acid analogues created by a biochemists at University of Cologne hrepresent a so called threofuranosyl nucleic acid...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...
AstraZeneca to take over Fusion Therapeutics Inc
Fusion Pharmaceuticals Inc‘s acquisition for US$2bn upfront marks a major step forward in AstraZeneca delivering on its ambition to transform cancer...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
Mogu Srl raises €11m to scale mycelium technology
Kering Ventures, and Progress Tech Transfer also participated in the €11m financing of Mogu Srl, which will change its company name to SQIM Srl. The...